NCT00061932 2021-02-02
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
12 trialsNCT00416793 2019-10-31
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00085410 2017-07-02
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00107341 2016-12-13
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00052507 2015-07-23
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00083226 2014-10-30
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052689 2013-10-08
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077441 2013-06-04
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00074009 2012-02-14
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103103 2010-10-13
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00051987 2008-02-11
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed